333 related articles for article (PubMed ID: 22178287)
1. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
[TBL] [Abstract][Full Text] [Related]
2. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
6. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
[TBL] [Abstract][Full Text] [Related]
10. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
Jiménez-Bonilla JF; Quirce R; Martínez-Rodríguez I; Banzo I; Rubio-Vassallo AS; Del Castillo-Matos R; Ortega-Nava F; Martínez-Amador N; Ibáñez-Bravo S; Carril JM
Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
[TBL] [Abstract][Full Text] [Related]
12. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
[TBL] [Abstract][Full Text] [Related]
14. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
[TBL] [Abstract][Full Text] [Related]
15. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
[TBL] [Abstract][Full Text] [Related]
16. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
[TBL] [Abstract][Full Text] [Related]
17. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
20. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
